ReviewTherapeutic advances in infectious disease2016
Carbapenem resistance: overview of the problem and future perspectives.
Review in Therapeutic advances in infectious disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06342115 (Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase), which is not on this map. Cited by 327 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.
Who cites it
327 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Prevalence of genes encoding carbapenem-resistance in Klebsiella pneumoniae recovered from clinical samples in Africa: systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Systematic review and meta-analysis on the carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates.BMC pharmacology & toxicology · 2025Pooled it
- Surveillance of carbapenem resistance in Asian countries: a systematic review and meta-analysis.BMJ open · 2024Pooled it
- The prevalence of colistin resistance in clinical Stenotrophomonas maltophilia isolates worldwide: a systematic review and meta-analysis.BMC microbiology · 2023Pooled it
- Prevalence of carbapenemase-producing Enterobacteriaceae from human clinical samples in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Pooled it
- The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.The Yale journal of biology and medicine · 2022Pooled it
- Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis.Systematic reviews · 2022Pooled it
- Carbapenem-resistantPublic health in practice (Oxford, England) · 2026Review
- The burden of antimicrobial resistance in Iraq: an analysis from 2021.IJID regions · 2026Article
- Risk factors associated with carbapenem-resistant Gram-negative bacterial infections in intensive care units in Jordan.BMC infectious diseases · 2026Article
- Distribution and antibiotic resistance profiles of uropathogens at Madan Bhandari Hospital, Nepal: Focus on multidrug and extensively drug-resistant strains.IJID regions · 2026Article
- Molecular Characterization of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2026Article
- Increased Prevalence of Multidrug-ResistantLife (Basel, Switzerland) · 2026Article
- Long-term epidemiology of bacterial pathogens and antimicrobial resistance in a secondary hospital in China: a 12-year retrospective study.BMC microbiology · 2026Article
- Epidemiology, Molecular Characteristics, Treatment Patterns, and Outcomes of Carbapenem-Resistant Enterobacterales Infections in a Tertiary Hospital in Southern Saudi Arabia: A Retrospective Cohort Study.Journal of epidemiology and global health · 2026Article
- Molecular characterization of extended-spectrum β-lactamases-producing Escherichia coli isolated from patients with bacteremia.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
267 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem resistance, mainly among Gram-negative pathogens, is an ongoing public-health problem of global dimensions. This type of antimicrobial resistance, especially when mediated by transferable carbapenemase-encoding genes, is spreading rapidly causing serious outbreaks and dramatically limiting treatment options. In this article, important key points related to carbapenem resistance are reviewed and future perspectives are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.